Cargando…

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines

Oncogenic mutations in BRAF are common in melanoma and thyroid carcinoma and drive constitutive activation of the MAPK pathway. Molecularly targeted therapies of this pathway improves survival compared to chemotherapy; however, responses tend to be short-lived as resistance invariably occursCell lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorris, Emma R., Blackshields, Gordon, Sommerville, Gary, Alhashemi, Mohsen, Dias, Andrew, McEneaney, Victoria, Smyth, Paul, O'Leary, John J., Sheils, Orla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910922/
https://www.ncbi.nlm.nih.gov/pubmed/26828826
http://dx.doi.org/10.1080/15384047.2016.1139230
_version_ 1782438056454782976
author Dorris, Emma R.
Blackshields, Gordon
Sommerville, Gary
Alhashemi, Mohsen
Dias, Andrew
McEneaney, Victoria
Smyth, Paul
O'Leary, John J.
Sheils, Orla
author_facet Dorris, Emma R.
Blackshields, Gordon
Sommerville, Gary
Alhashemi, Mohsen
Dias, Andrew
McEneaney, Victoria
Smyth, Paul
O'Leary, John J.
Sheils, Orla
author_sort Dorris, Emma R.
collection PubMed
description Oncogenic mutations in BRAF are common in melanoma and thyroid carcinoma and drive constitutive activation of the MAPK pathway. Molecularly targeted therapies of this pathway improves survival compared to chemotherapy; however, responses tend to be short-lived as resistance invariably occursCell line models of melanoma and thyroid carcinoma, +/− BRAF(V600E) activating mutation, were treated with the MEK inhibitor PD0325901. Treated and naive samples were assayed for expression of key members of the MAPK pathway. Global microRNA expression profiling of naive and resistant cells was performed via next generation sequencingand indicated pluripotency pathways in resistance. Parental cell lines were progressed to holoclones to confirm the miRNA stemness profileMembers of the MIR302/373/374/520 family of embryonic stem cell specific cell cycle regulating (ESCC) microRNAs were identified as differentially expressed between resistant BRAF(V600E) melanoma and thyroid cell lines. Upregulated expression of gene and protein stemness markers, upregulated expression of MAPK pathway genes and downregulation of the ESCC MIR302 cluster in BRAF(V600E) melanoma indicated an increased stem-like phenotype in resistant BRAF(V600E) melanoma. Conversely, downregulated expression of gene and protein stemness markers, downregulated expression of MAPK pathway genes, upregulation of the ESCC MIR520 cluster, reeexpression of cell surface receptors, and induced differentiation-associated morphology in resistant BRAF(V600E) indicate a differentiated phenotype associated with MEK inhibitor resistance in BRAF(V600E) thyroid cellsThe differential patterns of resistance observed between BRAF(V600E) melanoma and thyroid cell lines may reflect tissue type or de novo differentiation, but could have significant impact on the response of primary and metastatic cells to MEK inhibitor treatment. This study provides a basis for the investigation of the cellular differentiation/self-renewal access and its role in resistance to MEK inhibition.
format Online
Article
Text
id pubmed-4910922
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49109222016-06-29 Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines Dorris, Emma R. Blackshields, Gordon Sommerville, Gary Alhashemi, Mohsen Dias, Andrew McEneaney, Victoria Smyth, Paul O'Leary, John J. Sheils, Orla Cancer Biol Ther Research Paper Oncogenic mutations in BRAF are common in melanoma and thyroid carcinoma and drive constitutive activation of the MAPK pathway. Molecularly targeted therapies of this pathway improves survival compared to chemotherapy; however, responses tend to be short-lived as resistance invariably occursCell line models of melanoma and thyroid carcinoma, +/− BRAF(V600E) activating mutation, were treated with the MEK inhibitor PD0325901. Treated and naive samples were assayed for expression of key members of the MAPK pathway. Global microRNA expression profiling of naive and resistant cells was performed via next generation sequencingand indicated pluripotency pathways in resistance. Parental cell lines were progressed to holoclones to confirm the miRNA stemness profileMembers of the MIR302/373/374/520 family of embryonic stem cell specific cell cycle regulating (ESCC) microRNAs were identified as differentially expressed between resistant BRAF(V600E) melanoma and thyroid cell lines. Upregulated expression of gene and protein stemness markers, upregulated expression of MAPK pathway genes and downregulation of the ESCC MIR302 cluster in BRAF(V600E) melanoma indicated an increased stem-like phenotype in resistant BRAF(V600E) melanoma. Conversely, downregulated expression of gene and protein stemness markers, downregulated expression of MAPK pathway genes, upregulation of the ESCC MIR520 cluster, reeexpression of cell surface receptors, and induced differentiation-associated morphology in resistant BRAF(V600E) indicate a differentiated phenotype associated with MEK inhibitor resistance in BRAF(V600E) thyroid cellsThe differential patterns of resistance observed between BRAF(V600E) melanoma and thyroid cell lines may reflect tissue type or de novo differentiation, but could have significant impact on the response of primary and metastatic cells to MEK inhibitor treatment. This study provides a basis for the investigation of the cellular differentiation/self-renewal access and its role in resistance to MEK inhibition. Taylor & Francis 2016-02-01 /pmc/articles/PMC4910922/ /pubmed/26828826 http://dx.doi.org/10.1080/15384047.2016.1139230 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Research Paper
Dorris, Emma R.
Blackshields, Gordon
Sommerville, Gary
Alhashemi, Mohsen
Dias, Andrew
McEneaney, Victoria
Smyth, Paul
O'Leary, John J.
Sheils, Orla
Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
title Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
title_full Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
title_fullStr Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
title_full_unstemmed Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
title_short Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
title_sort pluripotency markers are differentially induced by mek inhibition in thyroid and melanoma brafv600e cell lines
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910922/
https://www.ncbi.nlm.nih.gov/pubmed/26828826
http://dx.doi.org/10.1080/15384047.2016.1139230
work_keys_str_mv AT dorrisemmar pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT blackshieldsgordon pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT sommervillegary pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT alhashemimohsen pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT diasandrew pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT mceneaneyvictoria pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT smythpaul pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT olearyjohnj pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines
AT sheilsorla pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines